SMN1 rs121908747: Understanding Silent Carrier Status in SMA
The rs121908747 variant is a specific genetic marker located within the SMN1 gene, which is primarily used to improve the detection of 'silent' carriers of spinal muscular atrophy (SMA). While most SMA carriers are identified by a simple loss of SMN1 copies, this variant helps identify individuals who carry two copies of the gene on a single chromosome, a condition that can otherwise lead to false-negative screening results.
What each genotype means
Typical residual carrier risk
You do not carry the linked marker associated with duplicated SMN1 alleles on a single chromosome. If clinical testing determines you have two SMN1 copies, this genotype does not elevate your baseline statistical risk of being a 2+0 silent carrier. However, it does not completely eliminate the residual risk of carrying a rare deletion or intragenic mutation.
Found in the vast majority of individuals across all major continental ancestral backgrounds.
Increased silent carrier probability
You carry one copy of the linked marker associated with duplicated SMN1 genes arranged in cis. If diagnostic copy-number screening identifies two copies of SMN1, carrying this marker statistically elevates the likelihood that both copies reside on one chromosome while the other chromosome carries an SMN1 deletion. The exact residual risk modification varies markedly by ancestral background and is highest in Ashkenazi Jewish and Asian populations.
Present in roughly 1% to 4% of individuals depending on ancestry, with higher frequencies observed in select cohorts.
Elevated silent carrier probability
You carry two copies of the linked marker associated with tandem SMN1 gene duplication events. In individuals with two total SMN1 gene copies, this genotype substantially increases the mathematical probability of a 2+0 silent carrier configuration. Comprehensive carrier risk assessment and genetic counseling are recommended to interpret this result alongside formal SMN1 dosage quantification.
Very rare across global populations, occurring in fewer than 1 in 1,000 individuals.
What is the rs121908747 Variant?
The rs121908747 variant is a single-nucleotide polymorphism (SNP) found within the SMN1 gene, located on chromosome 5. In the context of genetic screening, this marker is often utilized as a linked indicator to help identify individuals who are 'silent carriers' of spinal muscular atrophy. Unlike standard screening methods that rely solely on counting the total number of SMN1 gene copies, the presence of this specific variant provides additional information about how those copies are arranged on the chromosomes. Because the SMN1 gene is located in a complex, duplicated region of the genome, standard tests sometimes struggle to distinguish between a person with one copy on each chromosome and a person with two copies on one chromosome and zero on the other. By tracking markers like rs121908747, laboratories can more accurately identify these silent carriers, who are otherwise asymptomatic but still carry a risk of passing the condition to their children.
The Role of the SMN1 Gene
The SMN1 gene, or survival motor neuron 1, provides the essential instructions for producing the SMN protein. This protein is critical for the health and survival of motor neurons, which are the nerve cells in the spinal cord that control muscle movement. When the SMN1 gene is missing or non-functional, the body cannot produce enough SMN protein, leading to the degeneration of these motor neurons and the symptoms associated with spinal muscular atrophy (SMA). SMA is an autosomal recessive condition, meaning that an individual must inherit a non-functional copy of the gene from both parents to be affected. Because the SMN1 gene is located near a nearly identical gene called SMN2, the region is prone to complex genetic rearrangements. While SMN2 can produce a small amount of functional protein, it is generally insufficient to compensate for the loss of SMN1, which is why the integrity of the SMN1 gene is so vital for normal motor function.
Research and Clinical Significance
Research into SMA carrier screening has evolved significantly, moving from simple copy-number analysis to more sophisticated methods that include sequence-specific markers like rs121908747. Clinical studies have demonstrated that relying only on SMN1 copy number can result in a false-negative rate of approximately 5% to 29%, depending on the population, because standard tests cannot detect the '2+0' silent carrier genotype. The inclusion of markers like rs121908747 in screening panels is supported by moderate evidence, as it significantly improves the sensitivity of carrier detection. By identifying these silent carriers, clinicians can provide more accurate reproductive risk assessments for couples. It is important to note that this information is for educational purposes; individuals concerned about their carrier status or family history should consult with a genetic counselor or a medical professional to discuss appropriate testing and the implications of their specific genetic results.
Understanding Your Results
If you have received information regarding your status for this variant, it is essential to understand that this is a screening tool, not a diagnostic test for a medical condition. A 'carrier' status for SMA means you have a genetic change that could potentially be passed to offspring, but you are typically asymptomatic. Because the frequency of this variant and the prevalence of silent carriers vary significantly by ancestry, the interpretation of your results may depend on your specific ethnic background. You cannot use this information to diagnose yourself or others, nor should it be used to make independent medical decisions. If you are planning a family or have a family history of neuromuscular disease, the most effective step is to speak with a healthcare provider or a certified genetic counselor. They can interpret your results in the context of your full genetic profile and provide guidance on the next steps for you and your family.
How common is this variant?
The frequency of the rs121908747 variant and the prevalence of silent carriers are highly variable across different ancestral populations, necessitating population-specific risk assessments.
Frequently asked questions
What is a silent carrier of SMA?
A silent carrier is an individual who has two copies of the SMN1 gene on one chromosome and zero copies on the other. Because they have two copies, they may appear as a non-carrier on standard tests, but they can still pass the non-functional gene to their children.
Why is rs121908747 used in screening?
This variant acts as a linked marker that helps laboratories identify the '2+0' silent carrier genotype. By detecting this marker, tests can more accurately identify individuals who would otherwise be missed by simple copy-number analysis.
Does having this variant mean I have SMA?
No. Being a carrier for SMA means you have a genetic change that could be passed to your children, but you do not have the disease yourself. SMA is an autosomal recessive condition, meaning you would need to inherit a non-functional gene from both parents to be affected.
Should I get tested for this variant?
Carrier screening is generally recommended for individuals who are pregnant or planning a pregnancy, regardless of ethnicity. You should discuss the benefits and limitations of SMA carrier testing with your doctor or a genetic counselor.
Sources & further reading
Educational information only, last refreshed 10/19/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908747?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29